Nektar Therapeutics Executive Compensation
Nektar Therapeutics is a publicly traded company in the Healthcare sector.
Named Executive Officers — FY2025
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
Nektar Therapeutics discloses FY2025 compensation for 5 named executive officers, totaling $11.2M. Howard W. Robin, the President and Chief Executive Officer, accounts for 56% of that combined total.
Howard W. Robin's total compensation rose 66% year-over-year, from $3.8M in FY2024 to $6.3M in FY2025.
Cash compensation (salary plus bonus) made up 77% of Nektar Therapeutics's FY2025 tracked executive pay, with stock awards accounting for 45%. That's notably more stock-weighted than the typical Healthcare company in this dataset, where stock awards average 0% of tracked pay.
Among 78 other Healthcare companies in this dataset, Nektar Therapeutics's combined tracked executive pay of $11.2M ranks in the 47th percentile (industry median: $13.6M). Its highest-paid executive, Howard W. Robin, ranks in the 50th percentile for top-executive pay in the sector (industry median: $6.1M).